You are here

  • Home
  • Archive
  • Volume 79, Issue 10
  • Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Article metrics

Article menu
Download PDFPDF
Epidemiology
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

 

Online download statistics by month:

Online download statistics by month: July 2020 to September 2024

AbstractFullPdf
Jul 202023472304998
Aug 2020848809247
Sep 20201135950322
Oct 2020757676335
Nov 2020462397204
Dec 2020426358167
Jan 2021740648216
Feb 2021326288146
Mar 2021339310225
Apr 2021592560410
May 2021408369521
Jun 2021210179131
Jul 202123820996
Aug 2021278248129
Sep 202123620692
Oct 202131129496
Nov 202131429783
Dec 202127825770
Jan 202218516979
Feb 202217617552
Mar 202217815156
Apr 202220519447
May 202220217756
Jun 202214212331
Jul 202211310834
Aug 202213011630
Sep 202211810832
Oct 202211410321
Nov 202211910528
Dec 20221109724
Jan 202312511223
Feb 202311710218
Mar 202314011829
Apr 202313041
May 202340765
Jun 2023892710
Jul 202316771
Aug 202322985
Sep 2023162130
Oct 202323752
Nov 202314971
Dec 2023240107
Jan 2024221153
Feb 2024302111
Mar 202416271
Apr 202416785
May 2024188810
Jun 202421380
Jul 202418373
Aug 202419772
Sep 2024316134
Total16981114685109